Carmustine
Bicnu, Gliadel (carmustine) is a small molecule pharmaceutical. Carmustine was first approved as Bicnu on 1982-01-01. It is used to treat brain neoplasms, carcinoma, colonic neoplasms, ependymoma, and glioblastoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease and non-hodgkin lymphoma. The pharmaceutical is active against glutathione reductase, mitochondrial.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Bicnu, Gliadel (generic drugs available since 2018-09-11)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bicnu | New Drug Application | 2020-12-24 |
| carmustine | NDA authorized generic | 2023-04-26 |
| gliadel | New Drug Application | 2018-12-13 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9050 | Injection, carmustine, 100 mg |
Clinical
Clinical Trials
189 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 6 | 38 | 13 | — | 2 | 58 | |
| Central nervous system neoplasms | D016543 | 16 | 16 | 3 | — | — | 31 | ||
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 5 | 10 | 4 | — | 2 | 19 | |
| Glioblastoma | D005909 | EFO_0000515 | 5 | 13 | 5 | — | 1 | 19 | |
| Plasma cell neoplasms | D054219 | 1 | 9 | 2 | — | 1 | 12 | ||
| Multiple myeloma | D009101 | C90.0 | 1 | 5 | 3 | — | 1 | 10 | |
| Leukemia | D007938 | C95 | — | 7 | 2 | — | — | 9 | |
| Neoplasms | D009369 | C80 | 3 | 4 | 1 | — | 1 | 8 | |
| Glioma | D005910 | EFO_0000520 | 1 | 4 | 1 | — | — | 5 | |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | 3 | — | 1 | 5 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | C85.9 | 11 | 16 | — | — | 2 | 21 | |
| Hodgkin disease | D006689 | C81 | 6 | 11 | — | — | 2 | 15 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 6 | 8 | — | — | 2 | 11 | |
| Follicular lymphoma | D008224 | C82 | 3 | 5 | — | — | 2 | 7 | |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | 5 | — | — | 2 | 7 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | 5 | — | — | — | 6 |
| Gliosarcoma | D018316 | 1 | 4 | — | — | — | 4 | ||
| Burkitt lymphoma | D002051 | C83.7 | 2 | 1 | — | — | 2 | 4 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | — | 1 | — | — | 2 | 3 | |
| Waldenstrom macroglobulinemia | D008258 | C88.0 | — | 1 | — | — | 2 | 3 |
Show 37 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Extranodal nk-t-cell lymphoma | D054391 | C86.0 | — | — | — | — | 2 | 2 | |
| B-cell lymphoma marginal zone | D018442 | C88.4 | — | — | — | — | 2 | 2 | |
| Intraocular lymphoma | D064090 | — | — | — | — | 2 | 2 | ||
| Large-cell lymphoma immunoblastic | D016400 | — | — | — | — | 2 | 2 | ||
| Lymphomatoid granulomatosis | D008230 | C83.8 | — | — | — | — | 2 | 2 | |
| Adult t-cell leukemia-lymphoma | D015459 | C91.5 | — | — | — | — | 1 | 1 | |
| Hairy cell leukemia | D007943 | C91.4 | — | — | — | — | 1 | 1 | |
| Large granular lymphocytic leukemia | D054066 | — | — | — | — | 1 | 1 | ||
| Aids-related lymphoma | D016483 | EFO_1001365 | — | — | — | — | 1 | 1 | |
| Retinoblastoma | D012175 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CARMUSTINE |
| INN | carmustine |
| Description | Carmustine is a member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group. It has a role as an alkylating agent and an antineoplastic agent. It is a member of N-nitrosoureas and an organochlorine compound. |
| Classification | Small molecule |
| Drug class | antineoplastics (chloroethylamine derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=NN(CCCl)C(=O)NCCCl |
Identifiers
| PDB | — |
| CAS-ID | 154-93-8 |
| RxCUI | 2105 |
| ChEMBL ID | CHEMBL513 |
| ChEBI ID | 3423 |
| PubChem CID | 2578 |
| DrugBank | DB00262 |
| UNII ID | U68WG3173Y (ChemIDplus, GSRS) |
Target
Agency Approved
GSR
GSR
Organism
Homo sapiens
Gene name
GSR
Gene synonyms
GLUR, GRD1
NCBI Gene ID
Protein name
glutathione reductase, mitochondrial
Protein synonyms
epididymis luminal protein 75, epididymis secretory sperm binding protein Li 122m, glutathione S-reductase, GRase
Uniprot ID
Mouse ortholog
Gsr (14782)
glutathione reductase, mitochondrial (Q8C9Z6)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,554 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bicnu
, Carmustine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
393 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more